Cytosorbents (CTSO) Gross Profit (2011 - 2026)

Cytosorbents has reported Gross Profit for 16 years, with the latest figure at $6.1 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit fell 1.24% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $26.4 million (up 9.05% YoY), and the FY2025 full-year result was $26.5 million, up 6.45% from the prior year.
• Gross Profit for Q1 2026 stood at $6.1 million, down from $6.8 million in the prior quarter.
• The five-year high for Gross Profit was $6.9 million in Q1 2024, with the low at $3.6 million in Q3 2022.
• Historically, Gross Profit has averaged $5.9 million across 5 years, with a median of $6.1 million in 2026.
• Annual changes were most pronounced in 2022 — Gross Profit slumped 50.43% — and 2023, when it surged 55.0%.
• Cytosorbents' Gross Profit stood at $5.8 million in 2022, then retreated by 7.74% to $5.3 million in 2023, then grew by 17.77% to $6.3 million in 2024, then advanced by 8.78% to $6.8 million in 2025, then retreated by 9.91% to $6.1 million in 2026.
• The last three Gross Profit figures came in at $6.1 million (Q1 2026), $6.8 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.